



Ottawa Hull K1A 0C9

(21)	(A1)	2,139,756
(86)		1993/07/07
(43)		1994/01/20

(51) Int.Cl. ⁶ A61K 39/39; A61K 39/29; A61K 39/145; A61K 38/19

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Use of GM-CSF as a Vaccine Adjuvant

(72) Bonnem, Eric M. - U.S.A. ;
Chaudry, Imtiaz A. - U.S.A. ;
Stupak, Elliot - U.S.A. ;

(71) Schering Corporation - U.S.A. ;

(30) (US) 07/910,399 1992/07/08

(57) 11 Claims



Notice: This application is as filed and may therefore contain an incomplete specification.



USE OF GM-CSF AS A VACCINE ADJUVANT

Patent number: CA2139756
Publication date: 1994-01-20
Inventor: BONNEM ERIC M (US); CHAUDRY IMTIAZ A (US); STUPAK ELLIOT (US)
Applicant:
Classification:
- international: A61K39/39; A61K39/145; A61K38/19; A61K39/29
- european: A61K39/145; A61K39/29B; A61K39/39
Application number: CA19932139756 19930707
Priority number(s): US19920910399 19920708; WO1993US06298 19930707

Also published as:

 WO9401133 (A1)
 EP0651656 (A1)

Report a data error here

Abstract of CA2139756

The present invention is a method for enhancing the immune response of a mammal to a vaccine comprising administering to such a mammal an effective amount of GM-CSF in conjunction with a vaccine. The present invention further provides for a pharmaceutical composition comprising an effective amount of GM-CSF, a natural, synthetic or recombinant antigen and a pharmaceutically acceptable carrier.

Data supplied from the **esp@cenet** database - Worldwide